


iodacif

IODINE, FOLIC ACID & B12 VITAMIN

MILD-TO-MODERATE MATERNAL IODINE DEFICIENCY (ID): AN EMERGENT PUBLIC HEALTH ISSUE

ID is one of the **most common micronutrient deficiencies worldwide** and despite the program of Universal Salt Iodization recommended by WHO in 1993, recent studies demonstrate the **current persistence of mild-to-moderate ID in industrialized countries.**

Iodine nutrition during pregnancy in Europe based on urinary iodine excretion (µg/L) - 2015



2/3 of European countries having assessed iodine nutrition during pregnancy, have reported inadequate iodine intakes.



>34% of the European school-age children have inadequate iodine intakes.

ATTENTION DEFICIT & HYPERACTIVITY DISORDER (ADHD) IN CHILDREN

ADHD has become a growing concern and nowadays, its worldwide prevalence is estimated **between 3 to 7% of all children, expressing excessive inattention, hyperactivity, and impulsive behaviours.**

- ▶ **More and more studies focus on the correlation between mild-to-moderate iodine deficiency in pregnancy and behavioural problems in childhood, including ADHD.**



IODACIF, THE EARLY IODINE SUPPLEMENTATION FOR ADHD PREVENTION

NOTHING MORE, NOTHING LESS: TAILOR MADE

Iodacif is the one-a-day solution, clinically supported to prevent iodine deficiency and related behavioural problems in children. **Iodacif** contains a **specific combination of active ingredients** provided in adequate doses to comply with international recommendations:


- ➔ **IODINE: essential for brain development and prevention of children behavioural problems**
Iodacif contributes to reduce the **deficiency commonly observed in pregnant women** and replies to the need of supplementation programs required by many industrialized countries.
- ➔ **FOLIC ACID: protection against neural tube defects**
Folic acid has been proven to **prevent 72% of cases of spina bifida and anencephaly** and is **recommended for all women planning pregnancy.**
- ➔ **B12 VITAMIN: central role in the normal nervous functions**
B12 vitamin is recognized for its synergic and interdependent action with folic acid and allows its activation in the body.

Mode of action | See next page
Clinical studies | next page



MATERNAL IODINE NEEDS INCREASED BY > 50% DURING PREGNANCY

Fetal neural development is highly dependent of T3 and T4, two hormones produced by thyroid and mainly composed by iodine molecules. In case of mild-to-moderate maternal iodine deficiency, TSH levels are increased as a stimulatory mechanism for thyroid hormone secretion.




IODACIF, THE CLINICALLY PROVEN SOLUTION

CLINICAL STUDY 1:

Prospective population-based study conducted on 3,736 children to investigate the association of maternal thyroid function during the first half of pregnancy with behavioural problems in the offspring up to age 3 yo.

Externalizing score = attention problems & aggressive behaviour




HIGHER LEVELS OF MATERNAL TSH, A MARKER OF IODINE DEFICIENCY, IS LINKED TO MORE PRONOUNCED ATTENTION PROBLEMS & AGGRESSIVE BEHAVIOURS IN CHILDREN.

CLINICAL STUDY 2:

10-year prospective study conducted on 27 children to evaluate the direct causal relationship between mother exposition to iodine deficiency and ADHD.

- Area A:** Children of mother from a moderately iodine deficient area (N=16)
- Area B:** Children of mother from a marginally iodine sufficient area (N=11)

*p<0.05



68.7% OF WOMEN FROM IODINE DEFICIENT AREA HAVE GIVEN BIRTH TO ADHD POSITIVE CHILDREN.

TECHNICAL INFORMATION

- Actives:** Iodine, folic acid, B12 vitamin
- Presentation:** 30 tablets in blister
- Regulatory:** Food supplement
- Posology:** 1 tablet / day, 1 month before and at least 3 months after conception

IODA_CPHI_MAIL_1018_00

**TAILOR-MADE FORMULA
PREVENTION OF IODINE DEFICIENCY DISORDERS
FETAL BRAIN DEVELOPMENT - ONE-A-DAY SOLUTION**



All product related information (including but not limited to therapeutic indications), trademarks, brand names and trade-dress provided herein are used by STRAGEN mainly for B2B purposes, and are the sole property of STRAGEN or under exclusive license. Any use of trademarks or brand names or trade-dress stated herein requires a prior written agreement from STRAGEN.

stragen

STRAGEN PHARMA SA
Chemin du Pré-Fleuri 3 1228 Plan-les-Quates/Geneva Switzerland
tel +41 22 799 19 19 fax +41 22 799 19 99 info@stragen.ch www.stragen.ch

